

FOI 2802

23rd December 2024

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

PROSTATE CANCER

Q1. How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between 1st Jul 2024 to the end of Sep 2024, or latest 3-months for which data are available?

Name of medicine	Number patients treated
1.1 Abiraterone (Zytiga or generic abiraterone)	
1.2 Apalutamide (Erleada)	
1.3 Cabazitaxel (Jevtana or generic cabazitaxel)	
1.4 Darolutamide (Nubeqa)	
1.5 Enzalutamide (Xtandi)	

Q2. How many patients were treated with these products specifically for prostate cancer (ICD-10 code = C61) in the 3 months between 1st Jul 2024 to the end of Sep 2024, or latest 3-months for which data are available?

Name of medicine	Number patients treated
2.1 Docetaxel for prostate cancer	
2.2 Olaparib (Lynparza) for prostate cancer	
2.3 Talazoparib (Talzenna) for prostate cancer	

Q3. How many patients were treated with the following combinations in the 3 months between 1st Jul 2024 to the end of Sep 2024, or latest 3-months for which data are available?

Name of medicine	Number patients treated	
3.1 Darolutamide (Nubeqa) + Docetaxel + ADT		
3.2 Olaparib (Lynparza) + Abiraterone		

Androgen Deprivation Therapy (ADT) = hormonal treatments, such as bicalutamide, leuprorelin, triptorelin, degarelix, flutamide

Q4. How many patients received the following products for non-metastatic hormone sensitive prostate cancer in the 3 months between 1st Jul 2024 to the end of Sep 2024, or latest 3-months for which data are available?

Name of medicine	Number patients treated
4.1 Abiraterone	
4.2 Enzalutamide	

BLADDER CANCER

Q5. How many patients were treated for bladder cancer (ICD-10 code = C67*) with the following products in the 3 months between 1st Jul 2024 to the end of Sep 2024, or latest 3-months for which data are available?

Name of medicine	Number patients treated
5.1 Atezolizumab (Tecentriq)	
5.2 Avelumab (Bavencio)	
5.3 Erdafitinib (Balversa)	
5.4 Nivolumab (Opdivo)	
5.5 Pembrolizumab (Keytruda)	

Q6. Of the patients treated with nivolumab (Opdivo) for bladder cancer, how many were treated in the following settings in the 3 months between 1st Jul 2024 to the end of Sep 2024, or latest 3-months for which data are available?

Combination, monotherapy, adjuvant	Number patients treated
6.1 Nivolumab in combination with cisplatin and gemcitabine	
6.2 Nivolumab monotherapy as adjuvant treatment	
6.3 Nivolumab monotherapy in total	

ATEZOLIZUMAB (TECENTRIQ)

Q7. How many patients were treated with atezolizumab (Tecentriq) for the following cancer types in the 3 months between 1st Jul 2024 to the end of Sep 2024, or latest 3-months for which data are available?

Cancer type	Number patients treated
7.1 Lung Cancer	
7.2 Breast Cancer	
7.3 Hepatocellular Carcinoma	

Q8. How many of the patients treated with atezolizumab were treated in the following settings in the 3 months between 1st Jul 2024 to the end of Sep 2024, or latest 3-months for which data are available?

Combination, monotherapy, adjuvant	Number patients treated
8.1 Atezolizumab in combination with carboplatin and etoposide	
8.2 Atezolizumab as adjuvant treatment	
8.3 Atezolizumab in combination with bevacizumab, carboplatin and paclitaxel	

Response:

Your request for information regarding the number of patients treated with specific medicines between the July 2024 and September 2024 has now been considered and cannot be provided.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

Unfortunately we are unable to provide the information you have requested as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. It has been estimated that it would take more than 18 hours to locate and retrieve the requested information. In order to obtain this information and it would exceed the £450 limit and is therefore cost prohibitive. As your request is asking for cancer specific information, this is not easily available from our pharmacy JAC system and a review of patient records/systems would be required.

Email: foi.team@southerntrust.hscni.net